<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Up to 40% of patients with <z:hpo ids='HP_0001635'>heart failure</z:hpo> develop <z:hpo ids='HP_0000716'>depression</z:hpo>, and <z:hpo ids='HP_0000716'>depression</z:hpo> is an independent risk factor for cardiovascular mortality in this patient population </plain></SENT>
<SENT sid="1" pm="."><plain>Consequently, increasing numbers of patients with <z:hpo ids='HP_0001635'>heart failure</z:hpo> are treated with antidepressants </plain></SENT>
<SENT sid="2" pm="."><plain>Selective <z:chebi fb="19" ids="28790">serotonin</z:chebi> reuptake inhibitors are typically the antidepressant of choice since this drug class has limited cardiovascular toxicity </plain></SENT>
<SENT sid="3" pm="."><plain>However, little is known about the effects of selective <z:chebi fb="19" ids="28790">serotonin</z:chebi> reuptake inhibitors on autonomic cardiac regulation in <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>Here, indexes of cardiac autonomic control were evaluated before and during <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:chebi fb="0" ids="5118">fluoxetine</z:chebi> (FLX) treatment (20 mg·kg(-1)·day(-1), 5 wk) in rats that developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> after coronary artery ligation </plain></SENT>
<SENT sid="5" pm="."><plain>FLX reduced the low-frequency (LF) component of heart rate variability (HRV; P &lt; 0.01) as well as the sympathetic contribution to LF HRV (P &lt; 0.01) in both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> and sham-operated rats </plain></SENT>
<SENT sid="6" pm="."><plain>Both FLX and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> reduced high-frequency HRV (P &lt; 0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>Spontaneous baroreflex gain was decreased in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> rats 8 wk after ligation (P &lt; 0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>Cross-spectral coherence between the interbeat interval and mean arterial pressure was reduced in the LF domain 3 wk after ligation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> rats (P &lt; 0.01) and was further reduced after <z:hpo ids='HP_0011010'>chronic</z:hpo> FLX treatment (P &lt; 0.01) </plain></SENT>
<SENT sid="9" pm="."><plain>Plasma <z:chebi fb="2" ids="33567">catecholamines</z:chebi> and LF blood pressure variability were not affected by FLX </plain></SENT>
<SENT sid="10" pm="."><plain>Chronotropic responses to both efferent vagal nerve stimulation and <z:chebi fb="0" ids="6046">isoproterenol</z:chebi> administration were reduced in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> rats and by FLX (P &lt; 0.01), whereas inotropic responses to <z:chebi fb="0" ids="6046">isoproterenol</z:chebi> were reduced only in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> rats (P &lt; 0.01) </plain></SENT>
<SENT sid="11" pm="."><plain>These data indicate that <z:hpo ids='HP_0011010'>chronic</z:hpo> FLX reduces the responsiveness to autonomic output controlling cardiac rhythm and may further compromise autonomic regulation of cardiac function in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> </plain></SENT>
</text></document>